This story is part of a series about founders and experts discovered during the Frontiers Health’s event in Berlin (Germany), where innovative healthcare professionals and disruptive entrepreneurs presented their products, services and ideas. Got a story to tell? Let us know! Email us at [email protected].
In an era where artificial intelligence is reshaping every corner of the life sciences industry, EVERSANA is positioning itself at the center of a global transformation. From redefining commercialization infrastructures to embedding regulatory foresight and patient value into every algorithmic decision, the company is advancing what it calls the “Human‑in‑the‑Loop framework” — an approach that keeps human judgment at the core of AI‑driven operations.
In this exclusive interview, Faruk Capan, Chief Innovation Officer, and Mike Ryan, General Manager for Europe, discuss how EVERSANA’s integrated commercialization model is evolving to meet the complex demands of global markets. They shed light on the governance systems that safeguard compliance in AI‑enabled agencies, the scalability of Direct‑to‑Disease models across continents, and the growing imperative for transparency under emerging global pricing policies.
What emerges is a portrait of a company accelerating the shift toward a “Brave New Commercialization World” — one where data, discipline, and human insight converge to drive smarter, more compliant, and patient‑centric outcomes across the full life‑science ecosystem.
Probing Governance, Regulatory Foresight, and Measurable ROI (Faruk Capan, Chief Innovation Officer)
EVERSANA emphasizes that AI must be “designed with humans at the center”. How does this Human-in-the-Loop framework fundamentally change the definition of commercial agency strategy and what specific governance mechanisms ensure that the 20% human expertise maintains absolute accountability for regulatory compliance and brand integrity in the AI Agency Platform?
The industry has treated AI as something that can bolt onto existing workflows, but that approach simply recreates old inefficiencies with new technology layered on top. We believe that technology is vital, yes, but much more important is what we call the “Human‑in‑the‑Loop framework.” This approach positions AI as the engine that drives planning, creation and optimization, while reinforcing that people must remain a part of any strategy. That distinction is critical. AI accelerates the work, but people remain responsible for judgment, context and compliance.
In practice, this means that every step of the workflow is anchored to clear ownership. Strategy, content creation and review all run in parallel, with humans guiding the direction and approving the outcomes. The platform embeds regulatory and brand policies directly into generation, so outputs are created within compliant boundaries from the start rather than corrected at the end. References are bound to claims as they’re produced, audit trails are recorded automatically and every asset carries a full history of the decisions behind it. Nothing can progress without a named approver validating that it meets regulatory expectations and brand standards.
AI provides scale and speed, but accountability is never diluted while humans remain responsible for the decisions that truly shape outcomes.
Regulatory expectations around AI transparency and data governance continue to rise globally. How is EVERSANA ensuring that solutions remain compliant and adaptable? How does an AI‑enabled review framework help transform compliance from a bottleneck into a scalable capability across the commercialization process?
Globally, regulators are moving toward the same expectations: transparency, explainability, and responsible data governance. We build our AI solutions with those requirements in mind. Every model interaction, prompt and output is captured with full lineage so reviewers and regulators can see exactly how content was produced and what evidence supports it. Policies, from brand guidelines to regional regulatory rules, are codified within the system, allowing us to adapt quickly as expectations evolve across markets.
What transforms compliance is the shift from end‑stage review to inline governance. When AI generates content that is automatically claims‑bound, label‑aware and audience‑appropriate, reviewers are no longer starting from a blank page or hunting for discrepancies. They are validating work that is already aligned with policy. The system flags any variances, summarizes changes and guides reviewers to the areas that genuinely require attention.
This allows compliance to become a scalable capability as it is embedded directly into how work is created. The outcome is higher quality, faster throughput and complete auditability all while meeting the rising expectations of global regulators.
How will EVERSANA’s AI infrastructure evolve beyond marketing acceleration to enable more sophisticated capabilities in areas such as omnichannel orchestration, strategic pricing and market access analytics, and end‑to‑end commercialization efficiency?
Acceleration is the entry point, but the real opportunity lies in orchestrating the entire commercial ecosystem. We are expanding our AI infrastructure to connect strategy, content, access, field execution and performance measurement in a single environment. This will allow teams to design omnichannel journeys, test scenarios and optimize messaging based on real‑world signals all within the same governed framework that ensures compliance and brand consistency.
We’re also extending capabilities into pricing and market access, where AI can synthesize policy updates, HTA decisions, competitive movements and real‑world evidence to support scenario planning. The goal isn’t to replace expert judgment but to give teams faster insight into how assumptions, payer expectations or evidence gaps may influence recommended strategies.
As these capabilities evolve, governance becomes even more important. The same controls that protect content will apply to scenario models, data sources and strategic recommendations, ensuring that every output remains explainable and anchored to validated evidence.
What’s the vision here? Creating an ecosystem where marketing, market access and field teams operate with shared visibility — connected by AI that accelerates work, reduces friction and enables leaders to make decisions with clearer insight and greater confidence. That’s where AI unlocks its full value: not just in speed, but in elevating the impact of every part of the commercialization journey.
Examining Scalability, Financial Transparency, and Adherence (Mike Ryan, General Manager, Europe)
EVERSANA has a proven track record of bringing high-complex therapies for rare disease and orphan drugs to market. What is the roadmap for scaling these through programs, like Direct-to-Disease (DTD) models, into primary care or mass-market therapeutic areas, and what proprietary technology investment is required to maintain the same level of coordination when patient volumes increase exponentially?
Rare disease launches are extremely complex. And with complexity comes a critical element for customer to consider with partners – discipline. The partners that companies choose must have operating models that consider every detail, patient touchpoint, access hurdles, clinical integration, and so much more. We believe that a disciplined approach is not a niche capability. Rather, its paramount to success and should be the foundation of any program. And this foundation is built with decades of experience across regions and therapeutic areas.
So how do you get there? The roadmap for expanding from rare and orphan indications into primary care or mass-market categories starts with standardising what consistently works across geographies: structured patient onboarding, evidence-based education, coordinated clinical and access workflows, and a predictable path to therapy initiation. In Europe, this is even more difficult because of the constrained environment. Direct-to-patient promotion is prohibited. Reimbursement and prescribing methods vary tremendously by country and healthcare system. So a one-size-fits all approach simply won’t work.
This is where models like EVERSANA’s Direct-to-Disease (DTD) can really be impactful, but again, may vary by region. In markets where direct patient advertising is not permitted, this concept represents a deliberately designed, quasi-proprietary approach where engagement is centred on the disease, the care pathway, and the clinical ecosystem rather than the brand itself. In these instances, education, identification, referral support, and service coordination are orchestrated in a compliant way that still enables scale without breaching local promotional restrictions. DTD is not simply an alternative to Direct-to-Patient in Europe. Rather, it is often the only viable way to expand reach while maintaining regulatory integrity.
In practice, these models are rarely built in isolation. We actively collaborate with innovative health‑tech and digital health partners to extend and enhance these disease‑focused ecosystems — ensuring patients benefit from the most effective tools, services, and technologies available within local care pathways.
The other key element of DTD is that as programs scale, the model flexes. High-touch human support remains available for complex patients and clinical scenarios, while routine interactions, follow-ups, and administrative steps are progressively handled through digital enablement, automation, and guided self-service. The results? Scarce clinical and field resources can remain focused where they can drive the greatest impact, rather than being diluted as patient volumes increase. And when this is achieved, patients win.
The shift to a “Brave New Commercialization World” implies global integration. How does the adoption of the DTD model in the highly idiosyncratic U.S. market influence your advice to clients regarding their launch sequencing and patient access strategies in Europe or Asia-Pacific, where single-payer systems necessitate different models?
The idea of a “Brave New Commercialization World” is less about convergence on a single global model and more about learning how to operate across fundamentally different systems without losing coherence. The U.S. is often the most information-rich starting point, but it is also the most idiosyncratic. Direct-to-Patient (DTP) models in the U.S. are built in the context of a multi-payer environment, where health plans, PBMs, and employers play an active role in shaping access, affordability, and persistence. As a result, patient engagement strategies must be closely integrated with payer dynamics, benefit design, and real-time access management.
That reality directly influences how we advise clients on global launch sequencing. The U.S. experience is invaluable for helping teams understand where patients struggle, what support drives adherence, and how services must adapt as volumes scale. But it’s important to know it does not provide a template that can simply be exported. The European and Asia-Pacific regions operate on fundamentally different incentives. Single-payer or highly centralised systems place far greater emphasis on population-level evidence, clinical pathway alignment, and clearly defined boundaries around what constitutes acceptable patient support.
This is where the distinction between Direct-to-Patient and Direct-to-Disease becomes critical. In Europe, where direct patient promotion is restricted, our Direct-to-Disease models enable compliant engagement by focusing on disease education, referral pathways, and coordination with clinical teams rather than brand-led outreach. Success is determined less by payer navigation and more by how well the service model aligns with HTA expectations, hospital workflows, and national care standards, including supplier choice and oversight. In this context, launch sequencing is driven by reimbursement timing, evidence readiness, and the ability to support clinicians within existing systems, not by the speed at which demand can be stimulated.
In Asia-Pacific, the paradigm shifts again. Market entry decisions are shaped by country-specific reimbursement processes, distribution infrastructure, and local data requirements. Here, modularity becomes essential. Programs must be designed so that core elements — education, clinical coordination, outcomes tracking — can be deployed selectively, without over-engineering services that are misaligned with local norms or policy constraints.
Across all regions, the unifying principle is a multidisciplinary approach to patient access. Whether operating direct to patient, direct to disease or direct to payers, the objective is generally the same – to integrate medical, access, commercial, and technology capabilities into a single operating system. When services are built in modular components and supported by a common data and orchestration layer, manufacturers gain the flexibility to adapt globally while continuously refining the model based on real-world outcomes.
Ultimately, global integration does not mean global uniformity. It means designing access strategies that respect local systems, leverage insights where they are most predictive, and optimise patient access through coordinated, cross-functional execution — regardless of whether the entry point is the U.S., Europe, or Asia-Pacific.
Focusing on Logistical Outsourcing, Channel Strategy and Competitive Positioning (Mike Ryan)
Global reference pricing and emerging Most Favored Nation (MFN) policies are reshaping how manufacturers plan launches. How does EVERSANA guide clients in developing evidence and pricing strategies across key markets to protect U.S. and international price corridors, while ensuring sustainable access and payer alignment globally?
Global reference pricing and emerging MFN policies are forcing a fundamental shift in how manufacturers think about launch strategy. The central question is no longer simply “What is the right price?” but “What is the right sequence, supported by the right evidence, to sustain that price across interconnected systems over time?” That distinction is critical, particularly as U.S. MFN proposals increasingly look outward to international benchmarks.
EVERSANA’s role is to help clients understand — and actively manage — those interdependencies. Markets move at different speeds and operate under different incentives, but pricing decisions in one geography now echo far more quickly into others. Protecting U.S. and international price corridors therefore starts well before launch, with a deliberate, globally coordinated evidence and access strategy rather than a series of market-by-market decisions.
A consistent theme in our recent work and public commentary is the importance of market-specific evidence readiness within a globally coherent value narrative. HTA bodies in Europe and single-payer systems elsewhere are demanding increasingly robust clinical, economic, and real-world evidence, while U.S. payers are sharpening their own expectations around durability of benefit, outcomes, and budget impact. We guide teams to build evidence plans early that are modular but aligned. This ensures that data generated to support access in markets such as Germany or the U.K. also reinforces, rather than undermines, the clinical and economic rationale that supports U.S. pricing.
It’s also important to remember that sequencing matters just as much as evidence. In Europe, controlling the order of market entry, the use of confidential discounts, and the structure of access agreements is often the difference between preserving global price integrity and triggering unintended reference pricing consequences. In the U.S., emerging MFN dynamics heighten the need for discipline around which prices are visible, when, and in what context. This is an area where we are spending significant time with clients, including through our MFN-focused briefings and newsletters, to translate policy signals into practical launch decisions.
What ultimately differentiates a sustainable strategy is integration. Pricing, evidence generation, access pathways, and service design cannot be treated as separate workstreams. They must be orchestrated together, with a clear understanding of how payer expectations, HTA decisions, and policy mechanisms interact across regions. When that orchestration is done well, manufacturers are far better positioned to maintain price corridors, mitigate MFN exposure, and still deliver meaningful, sustainable access for patients globally.
In the end, the objective is not to avoid scrutiny. Rather, it is to be prepared for it, with a launch strategy that is deliberate, evidence-led, and globally coherent from day one. Very few providers can offer this holistic view under one roof. At EVERSANA, we’ve proven we can, on a global level.
As the industry moves toward value‑based care and EVERSANA accelerates its vision to ‘Pharmatize AI,’ what will success ultimately look like? In your view, what outcomes will define whether EVERSANA has truly transformed the life sciences sector through AI‑driven commercialization?
Faruk Capan:
Success, in my view, is measured by whether AI meaningfully improves the experience of patients, providers, and the teams responsible for getting therapies to market. “Pharmatizing AI” is not about applying technology to isolated problems; it is about embedding intelligence across the entire commercialization lifecycle so decisions become clearer, pathways become more connected, and the industry can operate with greater precision and reliability.
When we get this right, every part of the value chain will feel different.
Value‑based care requires this level of integration. It demands that manufacturers understand not just what they deliver, but how it performs in the real world and how quickly patients can access it. AI helps solve those challenges when it supports the people doing the work, giving commercial, medical and market access teams the insights and tools to anticipate obstacles before they arise.
Transformation will be evident when our clients can move faster with greater certainty; when they can enter new markets with more confidence in their evidence, pricing and access strategy; and when the experience for patients feels more consistent, coordinated and supported from the first moment of engagement. Success is when AI is no longer viewed as the operating fabric of commercialization. When that shift happens, the life sciences sector becomes more capable of delivering on its promise to patients.
This article was brought to you by Frontiers Health, which is one of the premier global health innovation events, with a strong focus on digital therapies, breakthrough technologies, healthcare transformation, investments, and ecosystem development. Frontiers Health is hosted and powered by EVERSANA.
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
